Faron, etusivu

releases and publications

Faron Pharmaceuticals Ltd: Director/PCA Dealing

Insider Transaction Regulatory

Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action

Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025

Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation

Insider Transaction Regulatory

Faron Pharmaceuticals Ltd: Registration of New Shares

Regulatory

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Regulatory

Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025

Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology

Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company

Regulatory

Faron’s Bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies

PreviousNext
Back to top